[Off-label use: update and relevance for urology].
The use of pharmaceuticals beyond the approved indication and conditions (off-label use) is of increasing public interest in times of necessary financial constraints in public health together with the high requirements for drug safety to protect the patient. Remarkably, more than half of the therapies in oncology are performed as off-label use. The discussion on off-label use is controversial and based on different points of interests. Evaluation of therapeutic agents by the pharmaceutical industry is predominantly driven by marketing and business requirements. As a consequence, treatment of rare diseases is often only possible by off-label use, creating more or less an off-label need. Reimbursement by health-care insurance is based on the approval of a pharmaceutical substance for a particular situation, because only the rigorous licensing process assures that the verified efficacy is higher than the, often severe, adverse side effects. It is a well known fact that the sometimes adverse events, which occur on administration of substances in an off-label fashion, are not included in the information on the regular use of a given drug. Finally, physicians request a controlled off-label use, which only allows experienced colleagues and (sub)-specialized oncologists to use pharmaceuticals in an off-label fashion. Up to date no legal documents exist that provide regulations for such an off-label usage.
Krege
S
S
Urologische Universitätsklinik Essen, Germany. susanne.krege@maria-hilf.de
Rohde
D
D
D017277:Drug Approval / Q000331:legislation & jurisprudence; D004341:Drug Evaluation; D004345:Drug Industry; D004348:Drug Labeling / Q000331:legislation & jurisprudence; D011307:Drug Prescriptions; D004363:Drug Utilization / Q000331:legislation & jurisprudence; D005858:Germany; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D035583:Rare Diseases / Q000188:drug therapy; D012307:Risk Factors; D014572:Urology